Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $190 at Chardan Capital Markets
-
EdtechX Holdings (NASDAQ:EDTX) Announces Transaction With Meten Education (China)
-
EdtechX Holdings (NASDAQ:EDTX) Announces Transaction With Meten Education (China)
-
EdtechX Holdings (EDTX) Announces Merger Agreement With Meten Education (China)
-
EdtechX Holdings (NASDAQ:EDTX) Announces Merger Agreement With Meten Education (China)
-
EdtechX Holdings (NASDAQ:EDTX) Announces Merger Agreement With Meten Education (China)
-
Rocket Pharmaceuticals (RCKT) PT Raised to $33 at Chardan Capital Markets
-
Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Chardan Capital Markets Downgrades Audentes Therapeutics (BOLD) to Neutral
-
Kodiak Sciences Inc. (KOD) Prices 6M Share Common Offering at $46/Sh
-
Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock
-
Chardan Capital Positive on Kodiak Sciences' (KOD) $225M Baker Bros. Royalty Deal
-
Arrowhead Research (ARWR) PT Raised to $81 at Chardan Capital Markets
-
Pre-Open Movers 11/27 (AVX) (MDR) (TNXP) Higher; (ARAV) (GES) (DELL) Lower (more...)
-
Ocugen (OCGN) Ramps 20%+ on New Buy Rating
-
Chardan Capital Markets Starts Ocugen, Inc. (OCGN) at Buy
-
Chardan Capital Markets Downgrades The Medicines Company (MDCO) to Neutral on Valuation, Removes as Top Pick
-
CRISPR Therapeutics (CRSP) Prices 4.25M Share Common Offering at $64.50/Sh
-
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
-
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
-
Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
-
OncoCyte Provides Corporate Update and Reports Third Quarter 2019 Financial Results
-
Chardan Capital Markets Upgrades Vascular Biogenics Ltd (VBLT) to Buy
-
Stone Street Group Initiates Coverage On BiomX Inc.
-
Iovanace Biotherapeutics (IOVA) PT Raised to $33 at Chardan Capital Markets
-
UPDATE: Chardan Capital Markets Starts Rocket Pharmaceuticals (RCKT) at Buy, Sees Over 100% Upside
-
Krystal Biotech (KRYS) PT Raised to $90 at Chardan Capital Markets
-
Scienjoy To Become A Public Company Via Business Combination With Wealthbridge
-
Dicerna Pharmaceuticals (DRNA) PT Increases to $20 at Chardan on Cash Infusion
-
Chardan Healthcare Acquisition Corp. Completes Merger with BiomX Ltd.
-
Chardan Capital Markets Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
-
Greenland Acquisition Corporation and Zhongchai Holding (Hong Kong) Limited Announce Closing of Business Combination
-
UPDATE: Chardan Capital Markets Starts PDS Biotechnology Corp (PDSB) at Buy
-
Form 8-K Chardan Healthcare Acqui For: Oct 23
-
Form DEFA14A Chardan Healthcare Acqui
-
Chardan Healthcare Acquisition Corp. Shareholders Approve Definitive Merger Agreement with BiomX Ltd.
-
Provention Bio Inc. (PRVB) PT Lowered to $18.50 at Chardan Capital Markets
-
PlacementTracker Publishes Q3 2019 PIPE and Private Placement Markets League Tables
-
Arrowhead Research (ARWR) PT Raised to $45 at Chardan Capital Markets After R&D Day
-
Form 8-K Chardan Healthcare Acqui For: Oct 21
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form 10-Q Chardan Healthcare Acqui For: Sep 30
-
Form 8-K Chardan Healthcare Acqui For: Oct 15
-
Form DEFA14A Chardan Healthcare Acqui
-
ProQR (PRQR) Prices 9.09M Share Offering at $5.50/Sh
-
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
-
Form 8-K Chardan Healthcare Acqui For: Oct 14
-
Form DEFA14A Chardan Healthcare Acqui
-
Kodiak Sciences Inc. (KOD) PT Raised to $35 at Chardan Capital Markets

